Mr. Dave Mason reports

HLS THERAPEUTICS REPORTS ANNUAL MEETING RESULTS

HLS Therapeutics Inc. has released voting results from its annual meeting of shareholders held in a virtual format on June 7, 2024.

A total of 21,098,254 common shares, or 66.32 per cent of the total common shares issued and outstanding, were voted based on proxies and votes received at the meeting. Details of the voting by individual director were as shown in the attached table.

Name of Nominee Votes Cast   FOR % of Vote Cast  FOR Votes   WITHHELD % of Votes  WITHHELD

John Welborn    18,209,962       88.85               2,284,420        11.15               
Craig Millian   19,959,739       97.39               534,643          2.61                
John Hanna      19,135,935       93.37               1,358,447        6.63                
Rodney Hill     19,959,554       97.39               534,828          2.61                
Laura Brege     19,118,129       93.28               1,376,253        6.72                
Norma Beauchamp 16,442,226       80.23               4,052,156        19.77               
Kyle Dempsey    19,032,703       92.87               1,461,679        7.13                
Christian Roy   19,135,933       93.37               1,358,449        6.63                

HLS also confirms that shareholders approved the appointment of Ernst & Young LLP as the Company's auditors with 21,098,117 votes (100%) cast "for" and 137 votes (0%) withheld.

ABOUT HLS THERAPEUTICS INC.

Formed in 2015, HLS is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. HLS's focus is on products targeting the central nervous system and cardiovascular therapeutic areas. HLS's management team is composed of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages.